RA Capital Management 13F holdings, Q1 2024
Holdings as of March 31, 2024 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 76 US equity positions worth $7.9bn in its Q1 2024 13F filing. The largest position was ASND at 19.4% of the reported book, followed by PCVX and LEGN. Against the Q4 2023 filing, it opened 9 new positions, added to 16 and reduced 2 among the top 50 holdings.
What did RA Capital Management own in Q1 2024? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2023 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A/S - ADR | Healthcare | 19.4% | $1.5bn | 10,108,400 | 0% | held |
| 2 | PCVX VAXCYTE INC | Healthcare | 7.1% | $560.4m | 8,203,754 | 4% | added |
| 3 | LEGN LEGEND BIOTECH CORP-ADR | Healthcare | 4.9% | $384.8m | 6,861,097 | 10% | added |
| 4 | JANX JANUX THERAPEUTICS INC | Healthcare | 4.4% | $345.1m | 9,165,652 | 0% | held |
| 5 | AEROVATE THERAPEUTICS INC | 3.1% | $244.4m | 8,263,982 | 0% | held | |
| 6 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 2.9% | $231.0m | 5,330,412 | 0% | held |
| 7 | EVH EVOLENT HEALTH INC - A | Healthcare | 2.4% | $188.1m | 5,736,132 | 125% | added |
| 8 | NEWAMSTERDAM PHARMA CO NV | 2.4% | $186.0m | 7,864,000 | 0% | held | |
| 9 | RXST RXSIGHT INC | Healthcare | 2.3% | $177.6m | 3,442,825 | 1% | added |
| 10 | TYRA TYRA BIOSCIENCES INC | Healthcare | 2.2% | $170.8m | 10,416,609 | 44% | added |
| 11 | EWTX EDGEWISE THERAPEUTICS INC | 2.1% | $162.5m | 8,909,091 | – | new | |
| 12 | 4D MOLECULAR THERAPEUTICS IN | 2.0% | $160.9m | 5,051,511 | 21% | added | |
| 13 | BIIB BIOGEN INC | Healthcare | 2.0% | $159.7m | 740,727 | 39% | added |
| 14 | PEPG PEPGEN INC | Healthcare | 2.0% | $157.1m | 10,689,545 | 31% | added |
| 15 | GERN GERON CORP | Healthcare | 1.9% | $152.5m | 46,202,425 | 0% | held |
| 16 | 89BIO INC | 1.9% | $148.6m | 12,766,948 | 12% | added | |
| 17 | DYN DYNE THERAPEUTICS INC | Healthcare | 1.8% | $140.7m | 4,954,779 | – | new |
| 18 | APGE APOGEE THERAPEUTICS INC | Healthcare | 1.7% | $131.4m | 1,977,901 | 0% | held |
| 19 | DAWNGBX DAY ONE BIOPHARMACEUTICALS I | 1.6% | $129.0m | 7,809,852 | 0% | held | |
| 20 | NKTX NKARTA INC | Healthcare | 1.5% | $116.8m | 10,805,129 | 38% | added |
| 21 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 1.4% | $112.3m | 18,202,009 | 0% | held |
| 22 | SPRY ARS PHARMACEUTICALS INC | Healthcare | 1.4% | $111.0m | 10,860,977 | 15% | added |
| 23 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 1.4% | $109.6m | 11,609,704 | 0% | held |
| 24 | VRNA VERONA PHARMA PLC - ADR | 1.3% | $101.7m | 6,317,990 | 0% | held | |
| 25 | LENZ LENZ THERAPEUTICS INC | Healthcare | 1.2% | $93.3m | 4,178,823 | – | new |
| 26 | INHIBRX INC | 1.2% | $91.9m | 2,629,837 | -44% | reduced | |
| 27 | AVIDITY BIOSCIENCES INC | 1.1% | $83.8m | 3,282,180 | 34% | added | |
| 28 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.0% | $79.8m | 1,000,000 | 0% | held |
| 29 | LONGBOARD PHARMACEUTICALS IN | 0.9% | $71.0m | 3,289,119 | – | new | |
| 30 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 0.9% | $70.0m | 2,333,000 | – | new |
| 31 | GHRS GH RESEARCH PLC | 0.8% | $66.6m | 6,251,714 | 12% | added | |
| 32 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 0.8% | $64.7m | 1,510,362 | 210% | added |
| 33 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 0.8% | $62.6m | 4,850,984 | 53% | added |
| 34 | ASTRIA THERAPEUTICS INC | 0.8% | $62.1m | 4,413,150 | – | new | |
| 35 | CGON CG ONCOLOGY INC | Healthcare | 0.8% | $61.3m | 1,397,433 | – | new |
| 36 | ABOS ACUMEN PHARMACEUTICALS INC | 0.8% | $60.5m | 14,932,063 | 0% | held | |
| 37 | ITEOS THERAPEUTICS INC | 0.8% | $60.3m | 4,417,259 | 0% | held | |
| 38 | SLDB SOLID BIOSCIENCES INC | Healthcare | 0.7% | $57.7m | 4,330,446 | 26% | added |
| 39 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 0.7% | $54.6m | 204,500 | 0% | held |
| 40 | VOR VOR BIOPHARMA INC | 0.7% | $53.9m | 22,748,880 | 0% | held | |
| 41 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 0.6% | $50.5m | 828,380 | – | new |
| 42 | URGN UROGEN PHARMA LTD | Healthcare | 0.6% | $46.3m | 3,083,430 | 0% | held |
| 43 | LRMR LARIMAR THERAPEUTICS INC | Healthcare | 0.6% | $45.9m | 6,045,351 | – | new |
| 44 | CTKB CYTEK BIOSCIENCES INC | Healthcare | 0.6% | $45.7m | 6,809,404 | 0% | held |
| 45 | CCCC C4 THERAPEUTICS INC | Healthcare | 0.5% | $39.9m | 4,878,000 | 0% | held |
| 46 | HOWL WEREWOLF THERAPEUTICS INC | 0.5% | $39.8m | 6,144,881 | 0% | held | |
| 47 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.5% | $37.3m | 2,122,465 | 0% | held |
| 48 | CLYM ELIEM THERAPEUTICS INC | 0.5% | $36.0m | 13,150,849 | 0% | held | |
| 49 | ACRV ACRIVON THERAPEUTICS INC | 0.4% | $34.4m | 4,810,508 | 0% | held | |
| 50 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 0.4% | $31.2m | 10,872,503 | -41% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.